MedTrace Logo

Promoting Kidney Recovery After Acute Kidney Injury Receiving Dialysis

NCT04948476 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2025-02-28

No results posted yet for this study

Summary

The overall goal of this study is to evaluate the feasibility of conducting a randomized controlled trial comparing a standardized dialysis strategy versus usual care (dialysis prescription ordered by each patient's primary nephrologist) in patients with AKI-receiving dialysis.

Conditions

Interventions

OTHER

Standardized Dialysis and Structured Discontinuation (S2D2)

Prescription to minimize dialysis-induced ischemia * Cool dialysate (35.0◦C) * Dialysate sodium of 145mmol/L * Dialysate calcium of 1.5mmol/L * Maximum ultrafiltration rate of 10mL/kg/hour (if no weight, maximum is 500mL/hour) * Note: If dialysis machines cannot get to the specified values, values closest to these are acceptable. Structured dialysis discontinuation (all criteria met) * Most recent pre-dialysis potassium \<6mmo/L and bicarbonate \>12mmol/L * Most recent urine volume ≥1L/day OR last ultrafiltration on dialysis \<1L/session * If available, timed urine collection with result for mean creatinine and/or urea clearance \>12mL/min

OTHER

Usual Care

Dialysis prescription ordered by their clinical team. Decisions on dialysis discontinuation will be left to individual clinicians and will not be guided by a standard protocol.

Sponsors & Collaborators

  • Unity Health Toronto

    collaborator OTHER

  • Samuel Silver

    lead OTHER

Principal Investigators

  • Samuel A Silver · Queen's University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-12
Primary Completion
2024-12-20
Completion
2024-12-20

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04948476 on ClinicalTrials.gov